Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents

Adult Male Anti-Inflammatory Agents 610 Opportunistic Infections Tertiary Care Centers Immunocompromised Host 03 medical and health sciences 0302 clinical medicine Crohn Disease Risk Factors 616 Republic of Korea Humans Tuberculosis Retrospective Studies Tumor Necrosis Factor-alpha Incidence Adalimumab Middle Aged Infliximab 3. Good health Treatment Outcome Colitis, Ulcerative Female
DOI: 10.3748/wjg.v21.i11.3308 Publication Date: 2017-09-17T23:09:13Z
ABSTRACT
AIM:To evaluate the incidence and risk factors of Korean tuberculosis (TB) infection in patients with inflammatory bowel disease (IBD) undergoing anti-TNF treatment. METHODS:The data IBD treated anti-TNFs 13 tertiary referral hospitals located southeastern region Korea were collected retrospectively.They failed to show response or intolerant conventional treatments, including steroids immunomodulators.Screening measures for latent TB (LTBI) Retrospective Study ORIGINAL ARTICLEactive after treatment identified. RESULTS:Overall, 376 agents recruited (male 255, mean age therapy 32.5 ± 13.0 years); 277 had Crohn's disease, 99 ulcerative colitis, 294 used infliximab, 82 adalimumab.Before treatment, screening tests LTBI an interferon gamma release assay a tuberculin skin test performed 82.2% patients.Thirty (8%) LTBI.Sixteen cases active one TB-related mortality occurred during 801 personyears (PY) follow-up (1997.4cases per 100000 PY) treatment.LTBI (OR = 5.76, 95%CI:1.57-21.20,P 0.008) WBC count < 5000 mm 3 4.5, 95%CI: 1.51-13.44,P 0.007) identified as independently associated factors. CONCLUSION:Anti-TNFs significantly increase IBD.The considerable burden marked immunosuppression might be attributed this risk.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (38)
CITATIONS (34)